Therapy Areas: Diabetes
ProtoKinetix Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants
20 July 2022 - - The University of Alberta has successfully completed Phase 1 clinical trial enrollment for the treatment of type 1 diabetes in islet cell transplants, US-based clinical-stage biomedical company ProtoKinetix, Inc (OTCQB: PKTX) said.

The molecule, PKX-001 (AAGP) successfully achieved, to date, the primary safety objectives. The trial is continuing with observation of the latest enrolled patients to monitor secondary objectives over the next six-months.

Following this period of follow-up, all secondary objectives will have been evaluated in all patients, and the data will be collated, analyzed, and reported.

The trial is being led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS director of Clinical Islet, Liver Transplant and Living Donor Liver Transplant Programs, Canada Research chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.


Related Headlines